Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Withdrawn 2Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 5Breast 4Gastrointestinal 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × bavituximab × Breast × Clear all
NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Peregrine Pharmaceuticals

Phase 2/3 Withdrawn
Breast

Breast Neoplasms

NCT00669591 2017-04-21

A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
46 enrolled
Breast

Breast Neoplasms

NCT02685306 2017-03-09

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Peregrine Pharmaceuticals

Phase 2 Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00669565 2011-03-24

Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
46 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡